

**Conflicts of Interest Management**  
**Performance Measurement Committee**  
 May 3, 2018

Name	COI	Agenda Items	Management this meeting <sup>1</sup>
<b>2018-19 Committee Members</b>			
Sameer Saini	<p><b>Moderate</b>                      Authored publication related de-intensification for diabetes treatment and hypertension treatment</p>	<p>2 Measures:                      1. NQF 0575: Comprehensive Diabetes Care: Diabetes Control: Hemoglobin A1c&lt;8%                      2. NQF 2602: Controlling High Blood Pressure for Patients with Serious Mental Illness</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>
Paul Shekelle	<p><b>Moderate</b>                      Authored publications related to intensive vs standard BP management; management of antiplatelet therapy; and interventions for bloodstream infections related to central catheters</p>	<p>3 Measures:                      1. NQF 2602: Controlling High Blood Pressure for Patients with Serious Mental Illness                      2. NQF 0371: Venous Thromboembolism Prophylaxis                      3. NQF 0139: Central Line Associated Bloodstream Infections</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>
Sandeep Vijan	<p><b>Moderate</b>                      Published comment letter related to diabetes risk assessment and glycemic control</p>	<p>1 Measure:                      1. NQF 0575: Comprehensive Diabetes Care: Diabetes Control: Hemoglobin A1c&lt;8%</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>

<sup>1</sup> Only conflicts that warrant restrictions (high and moderate) are reported. Please see full signed reports for complete list of disclosures from all meeting participants.

**Conflicts of Interest Management**  
**Performance Measurement Committee**  
 May 3, 2018

Name	COI	Agenda Items	Management this meeting
<b>Outgoing Committee Members</b>			
Andrew Dunn	<p><b>Moderate</b>                      Grant (funded by Pfizer, administered by The Joint Commission): Transitions of Care for Venous Thromboembolism</p>	<p>1 Measure:                      1. NQF 0371: Venous Thromboembolism Prophylaxis</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>
Stephen Persell	<p><b>High</b>                      Grant (funded by Omron Healthcare, Inc.): Improving Hypertension using a Smartphone-Enabled Personal Control Program: The Smart Hypertension Control Study</p>	<p>1 Measure:                      1. NQF 2602: Controlling High Blood Pressure for Patients with Serious Mental Illness</p>	<ul style="list-style-type: none"> <li>• Recused from discussion, authorship, and voting</li> </ul>
	<p><b>Moderate<sup>2</sup></b>                      Authored publications related to inappropriate antibiotic prescribing</p>	<p>1 Measure:                      1. NQF 2720: National Healthcare Safety network Antimicrobial Use Measure</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>
	<p><b>Moderate<sup>2</sup></b>                      Participated in the recent development of the measures, or developed competing measures</p>	<p>4 Measures:                      1. NQF 1654: TOB-2 Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a: Tobacco Use Treatment                      2. NQF 1659: Influenza Immunization                      3. NQF 0039: Flu Vaccinations for Adults Ages 18 and Older                      4. NQF 0027: Medical Assistance with Smoking and Tobacco use Cessation</p>	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>

<sup>2</sup> Individual is recused from authorship due to separate high-level conflict

**Conflicts of Interest Management**  
**Performance Measurement Committee**  
 May 3, 2018

Name	COI	Agenda Items	Management this meeting
Mark Metersky	<b>High</b> <sup>3</sup> Expert witness (personal injury and malpractice): sepsis and pulmonary embolism	2 Measures 1. NQF 0500: Severe Sepsis and Septic Shock: Management Bundle 2. NQF 0371: Venous Thromboembolism Prophylaxis	<ul style="list-style-type: none"> <li>• Recused from discussion, authorship and voting</li> </ul>
<b>ACP Staff (staff does not participate in voting)</b>			
Kate Carroll	<b>Moderate</b> Household member is employed by The Beasley Firm, LLC (personal injury and medical malpractice firm)	All clinical topic areas	<ul style="list-style-type: none"> <li>• Participates in discussion</li> <li>• Recused from voting</li> </ul>
Melissa Starkey	<b>High</b> Household member is employed by Teva Pharmaceutical Industries	All clinical topic areas	<ul style="list-style-type: none"> <li>• Recused from discussion and authorship</li> </ul>

<sup>3</sup> For this meeting, high COI will be managed based on relevance to the clinical topic areas included in the current measure review